OakChart

Champions Oncology Inc

CSBRHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 12:25 PM ET

4.84+0.09 (1.89%)
2026-11-11 19:03 CET
Market cap
66.11 USD m
Revenue, TTM
60.66 USD m
Net income, TTM
-1.10 USD m
Free cash flow, TTM
-6.14 USD m
EPS diluted, TTM
-0.08
P/E
-
Compare

Price

CSBR against its 20, 50 and 200-day averages
2050200earnings
5.006.007.0018K35KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CSBRclose 4.8420-day 4.8050-day 4.92200-day 5.664.8452w low

41.8% under the 52-week high of 8.31 on 15 Dec 2025. 52-week low 4.59 on 16 Sep 2026. Last 15 sessions, 9.8% high to low

Profile

CSBR
52-week range, 7% of the way up
4.598.31

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Employees214
IPOJun 15, 1992
Beta0.45
ATR, 14d0.18
Rel volume0.47
Short float1.20%
Insider own56.62%
Inst own18.81%

Snapshot

6 groups

Valuation

Index-
Market Cap67.36M
Enterprise Value74.54M
Income-1.10M
Sales60.66M
Book/sh0.28
Cash/sh0.31
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees214
IPOJun 15, 1992

Ratios

P/E-
Forward P/E-
PEG-
P/S1.11
P/B17.30
P/C15.45
P/FCF-
EV/EBITDA207.06
EV/Sales1.23
Quick Ratio1.03
Current Ratio1.03
Debt/Eq2.82
LT Debt/Eq2.60
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.08
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y40.02% -
Sales past 3/5Y3.33% 7.68%
EPS Y/Y TTM-136.61%
Sales Y/Y TTM6.65%
EPS Q/Q3.16%
Sales Q/Q8.84%
EarningsSep 10 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own56.62%
Insider Trans0.00%
Inst Own18.81%
Inst Trans-46.96%
ROA-3.46%
ROE-29.83%
ROIC-7.89%
Gross Margin47.69%
Oper. Margin-1.54%
Profit Margin-1.82%
SMA200.83%
SMA50-1.72%
SMA200-14.45%
Trades-

Technical

Shs Outstand13.92M
Shs Float6.04M
Short Float1.20%
Short Ratio6.91
Short Interest0.07M
52W High8.31 -41.76%
52W Low4.59 5.45%
Volatility2.47% 3.83%
ATR (14)0.18
RSI (14)49.64
Beta0.45
Rel Volume0.47
Avg Volume10.46K
Volume2,801

Performance

Perf Week0.21%
Perf Month-1.22%
Perf Quarter-4.72%
Perf Half Y-19.60%
Perf YTD-29.96%
Perf Year-30.86%
Perf 3Y-13.26%
Perf 5Y-52.17%
Perf 10Y170.39%
Recom1.00
Target Price12.00
Prev Close4.75
Price4.84
Change %1.89%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Sep 12, 2024UpgradeCCraig HallumHold → Buy$6+24.0%
Nov 18, 2019InitiatedTThe Benchmark CompanySpeculative Buy

Peers

Mkt cap
TickerCompanyMkt cap
CRLCharles River Laboratories International Inc16.81B
FTREFortrea Holdings Inc2.05B
CAICaris Life Sciences Inc7.04B
MEDPMedpace Holdings Inc18.67B
TEMTempus AI Inc14.82B
NEONeogenomics Inc2.19B
ICLRIcon Plc15.19B
CERTCertara Inc1.83B
PSNLPersonalis Inc1.73B
AZTAAzenta Inc2.19B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ACKERMAN JOELDirectorOct 15 '26Option Exercise1.6069,794111,6701,126,333Oct 16 12:45 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 204
  • BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award" (ACCESSWIRE)
  • Champions Oncology Inc (CSBR) (Q1 2027) Earnings Call Highlights: Data Licensing Surge and ... (GuruFocus.com)
  • Champions Oncology Reports Revenue of $15.2 Million (ACCESSWIRE)
  • Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026 (ACCESSWIRE)
  • Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging (ACCESSWIRE)
  • Loading…
  • Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ... (GuruFocus.com)
  • Champions Oncology Reports Record Annual Revenue of $59 Million (ACCESSWIRE) -8.75%
  • Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026 (ACCESSWIRE)
  • Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026 (ACCESSWIRE)
  • Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy (ACCESSWIRE)
  • Champions Oncology Inc (CSBR) Q3 2026 Earnings Call Highlights: Record Services Revenue and ... (GuruFocus.com) -5.97% +6.35%
  • Champions Oncology Reports Revenue of $16.6 Million (ACCESSWIRE) +6.27%
  • Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026 (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-09-100.050--0.03015.23--
2025Q42026-07-270.010--0.04813.84--
2025Q22025-12-150.0600.0000.01915.0414.041
2025Q12025-09-150.020-0.010-0.03214.0013.511
2024Q42025-07-23-0.070-0.200-0.13312.3612.001
2024Q32025-03-110.360-0.0100.31317.0412.901
2024Q22024-12-110.0500.0100.05213.5013.051
2024Q12024-09-110.110-0.0300.09414.1013.231
2023Q42024-07-180.010-0.160-0.00814.0012.701
2023Q32024-03-12-0.160-0.060-0.18612.0013.501
2023Q22023-12-13-0.150-0.163-0.15311.6012.823
2023Q12023-09-08-0.170-0.105-0.19012.5713.102
2022Q42023-07-24-0.170-0.080-0.18913.1012.841
2022Q32023-03-16-0.167-0.035-0.18012.7813.133
2022Q22022-12-130.0100.007-0.00114.3013.793
2022Q12022-09-080.0000.003-0.02413.7013.463

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-0.050-0.087-0.13020.2420.29
2018FY0.0500.0700.00927.0727.08
2019FY-0.1530.060-0.17732.1231.63
2020FY0.0700.0570.02541.0440.53
2021FY0.1100.1200.03949.1149.00
2022FY-0.326-0.290-0.39453.8753.64
2023FY-0.460-0.630-0.53750.2048.80
2024FY0.5100.3000.33056.9456.60
2025FY0.120--0.08059.43-
2026FY-0.100--65.26

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q2S2025-12-1610016.3716.3716.37
2026Q2R2025-12-16100-0.04-0.04-0.04
2026Q2E2025-12-161000.020.020.02
2026Q1S2025-12-1610015.0515.0515.05
2026Q1R2025-12-16100-0.07-0.07-0.07
2026Q1E2025-12-16100-0.01-0.01-0.01
2026FYS2026-03-0110065.2665.2665.26
2026FYS2025-12-1610165.2665.2665.26
2026FYS2025-11-3010067.1067.1067.10
2026FYS2025-11-1111067.1067.1067.10
2026FYS2025-11-1011067.1067.1067.10
2026FYS2025-11-0911067.1067.1067.10
2026FYS2025-11-0811067.1067.1067.10
2026FYS2025-11-0711067.1067.1067.10

Estimate history

EPS, annual-0.130.009-0.1770.0250.039-0.394-0.5370.33-0.085-0.0802
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0940.0520.313-0.133-0.0320.019-0.02-0.048-0.031
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual20.24127.06732.12341.0449.10953.8750.15556.94459.42560.66
Period201720182019202020212022202320242025TTM
Sales, quarterly14.06113.48917.03912.35513.99515.03516.55913.83515.232
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual11.00311.6212.72713.41413.52213.54413.55913.77713.88713.919
Period201720182019202020212022202320242025MRQ
Shares, quarterly13.59413.69913.70613.77713.78813.88613.88713.88713.919
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue60.6659.4256.9450.1653.8749.1141.0432.1227.07
Cost of Goods Sold Incl. D&A31.7332.2830.0329.4029.5323.6321.4517.0014.27
Gross Profit28.9327.1526.9120.7524.3425.4819.5915.1212.80
Selling, General and Administrative Excl. Other29.8628.1822.0727.6828.7924.8719.2316.7112.53
Research and Development9.359.086.839.5411.549.377.205.854.80
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-0.93-1.034.85-6.92-4.450.610.37-1.590.27
Interest Expense--0.030.030.000.00---
Unusual Expense0.000.000.00-0.810.00-0.070.34-
Net Income Before Taxes-0.89-0.934.63-7.31-5.270.580.44-1.960.23
Income Taxes0.240.25-0.07-0.030.070.040.070.130.10
Consolidated Net Income-1.14-1.184.70-7.28-5.330.550.36-2.090.13
Net Income From Continuing Operations-1.10-1.184.70-7.28-5.330.550.36-2.090.13
Net Income-1.10-1.184.70-7.28-5.330.550.36-2.090.13
EPS (Recurring)-0.08-0.080.33-0.54-0.350.040.02-0.160.01
EPS (Basic, Before Extraordinaries)-0.08-0.090.34-0.54-0.390.040.03-0.180.01
EPS (Diluted)-0.08-0.090.33-0.54-0.390.040.02-0.180.01
EBITDA0.360.356.49-5.05-1.253.021.95-0.360.88
Non-Operating Income (Expense)0.040.10-0.19-0.36-0.01-0.02-0.00-0.04-0.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.420.980.520.880.680.670.440.440.47
Price To Earnings Ratio--15.88--307.20523.41-1,713.21
Price To Sales Ratio1.231.391.791.311.242.213.812.854.73
Gross Margin47.6945.6847.2741.3845.1851.8847.7447.0847.30
Operating Margin-1.54-1.738.51-13.80-8.261.240.89-4.941.00
Net Margin-1.82-1.988.26-14.51-9.901.120.88-6.520.47
Shares Outstanding13.9213.8913.7813.5613.5413.5213.4112.7311.62
Market Capitalization66.1166.1198.8665.9366.71103.85143.6891.78105.46

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue15.2313.8416.5615.0413.9912.3617.0413.49
Cost of Goods Sold Incl. D&A7.857.099.187.628.357.677.017.83
Gross Profit7.386.757.387.425.644.6910.025.66
Selling, General and Administrative Excl. Other7.797.277.577.236.156.405.534.93
Research and Development2.342.122.272.622.081.961.721.69
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.41-0.52-0.190.18-0.51-1.714.500.73
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-0.41-0.49-0.240.26-0.45-1.964.520.74
Income Taxes0.010.170.040.020.01-0.130.020.01
Consolidated Net Income-0.43-0.67-0.280.24-0.47-1.834.500.73
Net Income From Continuing Operations-0.43-0.67-0.280.27-0.44-1.834.500.73
Net Income-0.43-0.67-0.280.27-0.44-1.834.500.73
EPS (Recurring)-0.03-0.05-0.020.02-0.03-0.130.310.05
EPS (Basic, Before Extraordinaries)-0.03-0.05-0.020.02-0.03-0.130.330.05
EPS (Diluted)-0.03-0.05-0.020.02-0.03-0.130.310.05
EBITDA-0.10-0.240.150.54-0.15-1.324.901.13
Non-Operating Income (Expense)-0.010.03-0.050.070.06-0.250.020.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.610.280.330.200.160.100.200.01
Price To Earnings Ratio--43.9334.2319.4515.88--
Price To Sales Ratio1.231.391.751.691.531.732.691.02
Gross Margin48.4848.7744.5949.3240.3137.9658.8341.97
Operating Margin-2.69-3.77-1.131.23-3.62-13.8726.405.43
Net Margin-2.80-4.82-1.681.78-3.12-14.8526.385.40
Shares Outstanding13.9213.8913.8913.8913.7913.7813.7113.70
Market Capitalization66.1182.77101.5194.3187.0798.86151.8753.15

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.879.792.6210.129.014.698.343.240.86
Short Term Receivables13.1811.239.538.019.516.994.774.383.92
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.171.351.501.331.140.960.390.310.29
Total Current Assets19.2222.3713.6419.4619.6612.6313.507.925.06
Net Property, Plant & Equipment7.229.4611.9714.5015.3614.616.792.552.08
Total Investments and Advances0.000.000.000.000.000.000.000.000.15
Intangible Assets0.340.340.340.340.340.340.340.670.67
Other Assets0.210.180.180.010.010.010.130.130.12
Total Assets26.9932.3426.1334.3135.3827.5920.7511.278.08
Short Term Debt Incl. Current Port. of LT Debt1.601.611.341.211.050.820.630.020.03
Accounts Payable6.904.255.805.332.871.893.142.812.15
Other Current Liabilities11.4218.0014.4015.1913.568.498.545.205.27
Total Current Liabilities19.9223.8521.5421.7317.4811.2012.308.037.45
Long Term Debt3.004.726.097.398.418.783.170.000.02
Provision for Risks Charges0.000.000.400.550.390.180.180.000.00
Other Liabilities0.000.000.000.000.000.000.001.000.61
Total Liabilities22.9228.5728.0429.6826.2820.1615.659.038.07
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity3.943.77-1.904.649.107.435.102.240.00
Total Shareholders Equity3.943.77-1.904.649.107.435.102.240.00
Accumulated Minority Interest0.130.000.000.000.000.000.000.000.00
Total Equity4.073.77-1.904.649.107.435.102.240.00
Total Liabilities & Stockholders Equity26.9932.3426.1334.3135.3827.5920.7511.278.08
Book Value Per Share0.280.27-0.140.340.670.550.400.190.00
Tangible Book Value Per Share0.260.25-0.170.320.650.530.370.14-0.06
Full-Time Employees21421321023023019414311592
Price to Book Ratio16.9817.92-34.569.4411.2419.3818.4847.1416,056.30
Return on Assets-3.9616.08-24.08-15.311.741.50-13.071.32-18.35
Return on Equity-30.48503.05-532.46-77.706.635.68-57.0511.42-732.51
Return on Invested Capital-16.9455.36-173.65-44.363.132.23-25.315.72-7,768.42
Quick Ratio0.960.940.630.901.131.131.100.990.68
Current Ratio0.960.940.630.901.131.131.100.990.68

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-1.14-1.184.70-7.28-5.330.550.36-2.090.13
Depreciation1.331.381.642.933.202.411.581.230.61
Other Funds (Non Cash)3.282.751.672.031.871.200.571.161.11
Funds from Operations3.482.958.01-2.31-0.274.162.520.291.84
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-9.04-7.42-0.62-3.824.242.34-4.202.610.02
Cash from Operating Activities-5.56-4.477.39-6.143.976.50-1.682.901.86
Capital Expenditures-0.57-0.56-0.39-0.84-2.87-2.38-3.28-2.22-0.83
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.020.020.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.110.000.00
Cash from Investing Activities-0.55-0.54-0.39-0.84-2.87-2.38-3.17-2.22-0.83
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.260.230.32-0.380.010.211.374.461.47
Repurchase of Common Pref Stock0.000.000.00-0.63-0.070.000.000.000.00
Sale of Common Pref Stock0.260.230.320.250.090.211.374.461.47
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.12-0.14-0.15-0.150.000.00-0.17-0.04-0.26
Change in Long Term Debt-0.12-0.14-0.15-0.150.000.00-0.17-0.04-0.26
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.12-0.14-0.15-0.150.000.00-0.17-0.04-0.26
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities0.150.100.17-0.530.010.211.204.421.20
Net Change in Cash-5.97-4.917.17-7.501.114.32-3.655.112.23
Free Cash Flow-6.14-5.047.00-6.971.104.11-4.960.691.03
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--14.58-60.5726.44-133.48124.51
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments4.364.877.138.5210.329.79
Short Term Receivables13.6013.1812.0711.549.4711.23
Inventories0.000.000.000.000.000.00
Other Current Assets1.331.170.991.281.221.35
Total Current Assets19.2919.2220.1821.3321.0122.37
Net Property, Plant & Equipment13.467.227.738.309.009.46
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.340.340.340.340.340.34
Other Assets0.200.210.200.200.200.18
Total Assets33.2926.9928.4530.1630.5532.34
Short Term Debt Incl. Current Port. of LT Debt0.871.601.611.621.621.61
Accounts Payable5.636.905.735.994.844.25
Other Current Liabilities12.2311.4213.3414.5316.2318.00
Total Current Liabilities18.7319.9220.6822.1422.7023.85
Long Term Debt10.103.003.393.794.314.72
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities28.8322.9224.0725.9327.0128.57
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3.893.944.284.173.513.77
Total Shareholders Equity3.893.944.284.173.513.77
Accumulated Minority Interest0.570.130.100.060.030.00
Total Equity4.464.074.384.233.543.77
Total Liabilities & Stockholders Equity33.2926.9928.4530.1630.5532.34
Book Value Per Share0.280.280.310.300.250.27
Tangible Book Value Per Share0.260.260.280.280.230.25
Full-Time Employees-214---213
Price to Book Ratio16.9819.3224.3426.8823.0817.92
Return on Assets-3.46-3.76-7.739.0010.6416.08
Return on Equity-29.83-28.89-46.80102.74185.89503.05
Return on Invested Capital-3.04-9.61-3.643.37-5.58-21.61
Quick Ratio1.030.960.980.960.930.94
Current Ratio1.030.960.980.960.930.94

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-0.43-0.67-0.280.24-0.47-1.83
Depreciation0.310.320.340.360.360.39
Other Funds (Non Cash)1.040.760.800.680.510.58
Funds from Operations0.930.410.871.270.40-0.86
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.42-2.41-2.21-3.000.207.73
Cash from Operating Activities-0.49-2.00-1.34-1.740.606.87
Capital Expenditures-0.06-0.24-0.04-0.24-0.05-0.25
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.020.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.06-0.24-0.01-0.24-0.05-0.25
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.050.000.000.210.020.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.050.000.000.210.020.01
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.02-0.02-0.04-0.04-0.04-0.04
Change in Long Term Debt-0.02-0.02-0.04-0.04-0.04-0.04
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.02-0.02-0.04-0.04-0.04-0.04
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.03-0.02-0.040.17-0.01-0.03
Net Change in Cash-0.51-2.25-1.39-1.810.546.58
Free Cash Flow-0.55-2.24-1.38-1.980.556.62
Price to Free Cash Flow--26.6017.5312.0414.05

Revenue breakdown

Pharmacology Services2024: 48.59M 2025: 57.13M
Product and Service, Other2024: 3.68M 2025: 1.53M
Translational Oncology Solutions (TOS) License2024: 4.68M 2025: 764.00K
United States2024: 56.94M 2025: 59.43M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.20%0.1M6.0M10.75K
2026-10-151.29%0.1M6.0M10.89K
2026-09-301.17%0.1M6.1M11.13K
2026-09-151.12%0.1M6.1M9.63K
2026-08-310.95%0.1M7.8M8.45K
2026-08-141.22%0.1M6.1M9.29K
2026-07-311.25%0.1M6.1M9.21K
2026-07-151.24%0.1M6.1M8.79K
2026-06-301.27%0.1M6.1M8.37K
2026-06-151.29%0.1M6.1M9.13K
2026-05-291.33%0.1M6.1M9.37K
2026-05-151.40%0.1M6.1M8.61K
2026-04-301.38%0.1M6.1M7.86K
2026-04-151.35%0.1M6.1M7.68K
2026-03-311.35%0.1M6.1M7.27K
2026-03-131.20%0.1M6.1M11.68K
2026-02-271.15%0.1M6.1M11.87K
2026-02-131.24%0.1M6.1M12.34K
2026-01-301.26%0.1M6.1M12.93K
2026-01-151.32%0.1M6.1M13.91K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.104.900.0035.0380.000.000.998-0.0090.000
call5.000.004.900.550.0003.000.000.0000.0000.000
call7.500.004.801.400.0003.000.000.691-0.1440.003
call10.000.004.900.0030.1590.000.000.987-0.0410.000
put2.500.000.050.050.00034.000.00-0.002-0.0090.000
put5.000.004.901.3029.6664.000.00-0.003-0.0140.000
put7.500.205.003.5010.1952.000.00-0.013-0.0400.000
put10.002.607.504.7011.2931.000.000.0000.0010.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-168-KCurrent report2026-10-14SEC
2026-09-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-07-31SEC
2026-09-108-KCurrent report2026-09-10SEC
2026-08-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-27SEC
2026-07-2710-KAnnual report pursuant to Section 13 or 15(d)2026-04-30SEC
2026-07-278-KCurrent report2026-07-27SEC
2026-03-308-KCurrent report2026-03-24SEC
2026-03-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-01-31SEC
2026-03-128-KCurrent report2026-03-12SEC
2026-01-304Statement of changes in beneficial ownership of securities2025-07-16SEC
2026-01-304Statement of changes in beneficial ownership of securities2021-11-05SEC
2026-01-163Initial statement of beneficial ownership of securities2021-06-09SEC
2025-12-1510-QQuarterly report pursuant to Section 13 or 15(d)2025-10-31SEC
2025-12-158-KCurrent report2025-12-15SEC
2025-11-074Statement of changes in beneficial ownership of securities2025-11-05SEC
2025-11-074Statement of changes in beneficial ownership of securities2025-11-05SEC
2025-11-074Statement of changes in beneficial ownership of securities2025-11-05SEC
2025-11-074Statement of changes in beneficial ownership of securities2025-11-05SEC
2025-11-074Statement of changes in beneficial ownership of securities2025-11-05SEC
2025-11-064Statement of changes in beneficial ownership of securities2025-10-30SEC
2025-10-168-KCurrent report2025-10-16SEC
2025-09-1510-QQuarterly report pursuant to Section 13 or 15(d)2025-07-31SEC
2025-09-158-KCurrent report2025-09-15SEC
2025-08-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Battery Management Corp.17.44%
NEA Management Company, LLC12.34%
VANGUARD CAPITAL MANAGEMENT LLC2.17%
TOCQUEVILLE ASSET MANAGEMENT L.P.2.13%
MORGAN STANLEY1.70%
BANK OF AMERICA CORP /DE/1.54%
RENAISSANCE TECHNOLOGIES LLC1.00%
BlackRock, Inc.0.94%
Mink Brook Asset Management LLC0.80%
GEODE CAPITAL MANAGEMENT, LLC0.55%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.66%
VANGUARD EXTENDED MARKET INDEX FUND0.45%
Fidelity Extended Market Index Fund0.22%
iShares Micro-Cap ETF0.20%
Fidelity Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.08%
Fidelity Series Total Market Index Fund0.07%
Schwab Total Stock Market Index Fund0.05%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.05%
Small Cap Core Fund0.03%

OakChart. CSBR. Cached 15 minutes.